目錄:北京博蕾德科技發(fā)展有限公司>>Biomedica Gruppe>>骨代謝>> Sclerostin（SOST） ELISA Kit
Sclerostin （SOST）ELISA 檢測試劑盒
Cat.No.:BI-20492
應(yīng)用領(lǐng)域：
1）腎病檢測
2）腫瘤誘導(dǎo)的骨病
3）代謝病治療的療效監(jiān)測，例如：甲狀旁腺治療的監(jiān)測。
4）風(fēng)濕性關(guān)節(jié)炎
5）骨質(zhì)疏松癥
試劑盒特點：
檢測方法：夾心ELISA,HRP/TMB顯色系統(tǒng)
樣本類型：血清、血漿（EDTA或肝素抗凝）、尿樣（參照對應(yīng)的protocol）
樣品量：20ul/test
標(biāo)準(zhǔn)品范圍：0-240 pmol/L
檢測靈敏度：2.6pmol/L
孵育條件：overnigh/1小時/30分鐘（室溫）
單位轉(zhuǎn)換：1pg/ml=0.044pmol
參考文獻：Sclerostin與腎病、糖尿病、心臟主動脈瓣硬化患者的關(guān)系。
Sclerostin: another bone-related protein related to all-cause mortality in haem dialysis? Viaene L et al., Nephrol Dial Transplant, 2013; 10.1093/ndt/gft039 |
The Relation between Renal Function and Serum Sclerostin in Adult Patients with CKD. Pelletier S et al., Clin J Am Soc Nephrol, 2013; 8: 819-823 |
Sclerostin and DKK-1 levels in pre-dialyisis CKD patients. Behets G et al., Nephrol Dial Transplant, 2012; 27: ii36-ii37 |
Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Cejka D et al., Nephrol Dial Trans-plant, 2012; 27: 226-230 |
Sclerostin Levels Associated with Inhibition of the Wnt/β-Catenin Signaling and Reduced Bone Turnover in Type 2 Diabetes Mellitus. Gaudio A et al., J Clin Endocrinol Metab, 2012; 97: 3744–3750 |
Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes. Gennari L et al., J Clin Endo Metab, 2012; 97: 1737-1744 |
Association of Sclerostin levels with the severity of aortic valve calcification. Koos et al., JACC, 2011; 57, 14 |
Serum Sclerostin levels are associated with aortic valve calcification in prevalent ha-emodialysis patients. Türkvatan A et al., Nephrol Dial Transplant, 2013; 28: i19–i21 |
Circulating Sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Thambiah S et al., Calcif Tissue Int, 2012; 90(6): 473-480 |
(空格分隔,最多3個,單個標(biāo)簽最多10個字符)
13
化工儀器網(wǎng)